24/7 Wall St.

Stocks were indicated sharply higher on Tuesday morning, likely with a thin-volume in trading participation this week. The stock market is still fighting for a positive 2015, but the trend that has endured for over four years now is that investors have bought every single market pullback.

24/7 Wall St. reviews dozens of analyst research reports each morning of the week to find new investing and trading ideas for its readers. Some of these analyst reports cover stocks to buy, and other calls cover stocks to sell or avoid.

As a reminder, 14 strategists are calling for a positive, but mixed, S&P 500 performance in 2016.

These are this Tuesday’s top analyst calls.

Albemarle Corp. (NYSE: ALB) was reiterated as Buy at Jefferies, but the price target was raised to $65.00 from $58.00 in the call. Jefferies believes the jump in the highly illiquid spot lithium market is an incremental positive.

Atara Biotherapeutics Inc. (NASDAQ: ATRA) was reiterated as Buy with a $47.00 price target (versus a $22.77 prior close) at Canaccord Genuity. The firm noted that the Chimerix drug study failure is an incremental positive for Atara. Canaccord sees its valuation only assuming a 55% chance that its EBV and CMV programs are successful.

24/7 Wall St.
8 Analyst Stock Picks With 50% to 100% Implied Upside